Circadian Clock Modulating Drugs for Sleep Disorders and Diabetes Treatment

Two types of seed small molecule compounds (CRY1-A, CRY2-A) that selectively activate the circadian clock regulators CRY1 and CRY2, respectively.

New Chemical Material: Hydrogen Boride “HB” Works as Fuel Cell Electrode Material Using Low Platinum, High-density Hydrogen Storage Material, and Highly Efficient Carbon Monoxide Synthesis Catalyst

Low-Loss Bidirectional Isolated DC-DC Converter

Applications for Onboard Chargers in V2G Electric Vehicles and Semiconductor Transformers (SST)

Hepatocarcinogenesis Risk Diagnostic Markers

Fibulin3 and GPNMB in serum of patients with MASLD as a direct biomarkers for assessing the risk of developing liver cancer.

X-ray microscopes with high robustness and reduced costs for design, manufacturing, installation, and maintenance

Bone Formation Promoter for Fractures, Spinal Fixation, Osteoporosis

A complex of bone morphogenetic protein (BMP2, FGF2, etc.) and polysulfated glycopeptide promotes bone formation by specifically delivering, accumulating, and maintaining the concentration of BMP2 on the bone surface.

Protocol for induction of Plateable primary hepatocytes from Suspension-type

A combination of extracellular matrix (ECM) and supplements can obtain highly useful plateable human primary hepatocytes from inexpensive suspension-type

Anti-miRNA Anticancer Drugs

Improved S-TuD (Synthetic Tough Decoy) RNA nucleic acid that inhibits miR-200 family, which is highly expressed in mammary cancer, colon cancer, endometrial cancer, ovarian cancer, etc.

Combination of IDO1 and COX2 inhibitors for cancer treatment

Focus on immune evasion mechanisms and cancer metabolism

Fusion Protein Anticancer Drug Targeting RAS

Fusion protein X, which combines a RAS-binding domain, a cell membrane-permeable peptide, and a third domain, inhibits the function of activated RAS and degrades it.